Evotaz FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved January 29, 2015)
Brand name: Evotaz
Generic name: atazanavir and cobicistat
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: HIV Infection
Evotaz (atazanavir and cobicistat) is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1infection in adults and pediatric patients weighing at least 35 kg.
Development timeline for Evotaz
|Jan 29, 2015||Approval FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults|
|Apr 14, 2014||Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.